Exelixis, Inc. (NASDAQ:EXEL) Stock Position Lowered by Amalgamated Bank

Amalgamated Bank decreased its position in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 27.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 168,482 shares of the biotechnology company's stock after selling 63,427 shares during the quarter. Amalgamated Bank owned about 0.06% of Exelixis worth $3,998,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of EXEL. Fifth Third Bancorp increased its holdings in shares of Exelixis by 44.2% in the third quarter. Fifth Third Bancorp now owns 1,970 shares of the biotechnology company's stock valued at $43,000 after buying an additional 604 shares in the last quarter. Alaska Permanent Fund Corp increased its holdings in shares of Exelixis by 1.2% in the 1st quarter. Alaska Permanent Fund Corp now owns 53,239 shares of the biotechnology company's stock valued at $1,263,000 after purchasing an additional 617 shares during the period. Signaturefd LLC lifted its position in shares of Exelixis by 17.1% in the third quarter. Signaturefd LLC now owns 4,577 shares of the biotechnology company's stock worth $100,000 after purchasing an additional 668 shares in the last quarter. Fisher Asset Management LLC boosted its holdings in shares of Exelixis by 232.6% during the fourth quarter. Fisher Asset Management LLC now owns 1,041 shares of the biotechnology company's stock worth $25,000 after purchasing an additional 728 shares during the period. Finally, Treasurer of the State of North Carolina grew its position in Exelixis by 0.5% during the third quarter. Treasurer of the State of North Carolina now owns 145,343 shares of the biotechnology company's stock valued at $3,176,000 after purchasing an additional 738 shares in the last quarter. Institutional investors own 85.27% of the company's stock.

Exelixis Price Performance

Shares of NASDAQ EXEL traded up $0.16 during trading hours on Friday, hitting $20.57. 1,704,028 shares of the stock were exchanged, compared to its average volume of 2,250,226. Exelixis, Inc. has a one year low of $18.64 and a one year high of $24.34. The company's 50 day moving average is $22.64 and its 200 day moving average is $22.30. The firm has a market capitalization of $6.24 billion, a P/E ratio of 32.14, a P/E/G ratio of 0.50 and a beta of 0.57.

Exelixis (NASDAQ:EXEL - Get Free Report) last released its quarterly earnings results on Tuesday, April 30th. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.28 by ($0.16). The firm had revenue of $425.23 million for the quarter, compared to the consensus estimate of $461.04 million. Exelixis had a net margin of 11.10% and a return on equity of 8.85%. The firm's revenue was up 4.0% on a year-over-year basis. During the same quarter last year, the company earned $0.12 earnings per share. Research analysts anticipate that Exelixis, Inc. will post 1.16 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on EXEL. William Blair reiterated an "outperform" rating on shares of Exelixis in a research report on Wednesday, May 1st. HC Wainwright reissued a "buy" rating and set a $28.00 price objective on shares of Exelixis in a research report on Friday, May 3rd. Royal Bank of Canada boosted their target price on Exelixis from $26.00 to $28.00 and gave the company an "outperform" rating in a research note on Wednesday, February 7th. Stephens began coverage on Exelixis in a research note on Tuesday, May 14th. They set an "equal weight" rating and a $23.00 price target for the company. Finally, TheStreet upgraded Exelixis from a "c+" rating to a "b-" rating in a report on Monday, March 18th. Seven investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Exelixis has an average rating of "Moderate Buy" and a consensus target price of $26.13.

Insider Buying and Selling at Exelixis

In other Exelixis news, Director George Poste sold 11,686 shares of Exelixis stock in a transaction that occurred on Tuesday, May 21st. The stock was sold at an average price of $20.96, for a total value of $244,938.56. Following the transaction, the director now directly owns 213,907 shares of the company's stock, valued at approximately $4,483,490.72. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other Exelixis news, Director George Poste sold 11,686 shares of the firm's stock in a transaction on Tuesday, May 21st. The shares were sold at an average price of $20.96, for a total value of $244,938.56. Following the sale, the director now directly owns 213,907 shares in the company, valued at approximately $4,483,490.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jack L. Wyszomierski sold 10,923 shares of the business's stock in a transaction dated Monday, May 13th. The stock was sold at an average price of $21.37, for a total transaction of $233,424.51. Following the transaction, the director now owns 338,948 shares in the company, valued at approximately $7,243,318.76. The disclosure for this sale can be found here. Insiders have sold 41,814 shares of company stock valued at $939,475 in the last 90 days. 2.85% of the stock is currently owned by insiders.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.